Keywords: ViiV Heathcare, Pfizer, GlaxoSmithKline, Shionogi, HIV integrase inhibitor, S/GSK1349572
ViiV Healthcare committed to Phase III development program for investigational once-daily HIV integrase inhibitor
Article | 22 July 2010
ViiV Healthcare, a joint venture between US drugs behemoth Pfizer (15% ownership) and the UK giant GlaxoSmithKline (85% holding) and collaboration with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
